Q1 2026 Management View CEO Thomas McCourt said 2026 priorities remain “maximizing LINZESS, advancing apraglutide and delivering sustained profits and cash flow,” and highlighted Q1 execution across ...
Ironwood Pharmaceuticals reaffirmed its 2026 financial guidance, including $1.125B–$1.175B in U.S. LINZESS sales, as it approaches a May 24 FDA decision on a pediatric indication. Q1 saw 97% year-over ...
U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – ...
"In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7 million ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Linzess comes as an oral capsule. It belongs to a class of drugs called guanylate cyclase-C agonists. At this time, Linzess is only available in a brand-name form. There’s currently no generic version ...
Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...
Linzess may interact with anticholinergic drugs, such as oxybutynin (Ditropan XL), and antidiarrheal drugs, such as loperamide (Imodium). Taking these drugs with Linzess can make Linzess less ...
Linzess is a prescription medication for adults that treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The typical dosage of Linzess for IBS-C is 290 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results